cellular
immunity
immunotherapy
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
accepted:
02
10
2020
entrez:
1
12
2020
pubmed:
2
12
2020
medline:
18
9
2021
Statut:
ppublish
Résumé
Microorganisms that can be used for their lytic activity against tumor cells as well as inducing or reactivating antitumor immune responses are a relevant part of the available immunotherapy strategies. Viruses, bacteria and even protozoa have been largely explored with success as effective human antitumor agents. To date, only one oncolytic virus-T-VEC-has been approved by the US Food and Drug Administration for use in biological cancer therapy in clinical trials. The goal of our study is to evaluate the potential of a livestock pathogen, the protozoan We demonstrated that the treatment of murine thymoma EG7 by subcutaneous injection of These results highlight
Sections du résumé
BACKGROUND
Microorganisms that can be used for their lytic activity against tumor cells as well as inducing or reactivating antitumor immune responses are a relevant part of the available immunotherapy strategies. Viruses, bacteria and even protozoa have been largely explored with success as effective human antitumor agents. To date, only one oncolytic virus-T-VEC-has been approved by the US Food and Drug Administration for use in biological cancer therapy in clinical trials. The goal of our study is to evaluate the potential of a livestock pathogen, the protozoan
METHODS/RESULTS
We demonstrated that the treatment of murine thymoma EG7 by subcutaneous injection of
CONCLUSION
These results highlight
Identifiants
pubmed: 33257408
pii: jitc-2020-001242
doi: 10.1136/jitc-2020-001242
pmc: PMC7705568
pii:
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: No, there are no competing interests.
Références
Oncotarget. 2015 Oct 20;6(32):33165-77
pubmed: 26431376
Surgery. 2015 May;157(5):888-98
pubmed: 25731784
Cancer Res. 2013 Jul 1;73(13):3842-51
pubmed: 23704211
Curr Opin Immunol. 2018 Apr;51:197-203
pubmed: 29730057
Parasitology. 2006 Jan;132(Pt 1):29-36
pubmed: 16393351
Mol Ther Oncolytics. 2016 Feb 17;3:16001
pubmed: 27119116
Expert Rev Vaccines. 2013 May;12(5):493-504
pubmed: 23659298
Infect Immun. 2000 Aug;68(8):4822-6
pubmed: 10899898
Mol Ther. 2007 Sep;15(9):1686-93
pubmed: 17579581
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19695-700
pubmed: 22114198
Mol Cell Biol. 1995 Jan;15(1):87-93
pubmed: 7799972
Cancer Immunol Res. 2015 Aug;3(8):891-901
pubmed: 25804437
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
J Immunol. 2013 Jan 1;190(1):469-78
pubmed: 23225891
Science. 1968 Apr 5;160(3823):72-4
pubmed: 4966746
Infect Immun. 2003 Sep;71(9):5254-65
pubmed: 12933872
Infect Immun. 2010 Feb;78(2):651-60
pubmed: 19995895
Nat Rev Clin Oncol. 2019 Aug;16(8):469-493
pubmed: 30816337
Mol Ther. 2019 Jun 5;27(6):1139-1152
pubmed: 31053413
J Infect Dis. 1971 Jan;123(1):22-31
pubmed: 5543220
Nature. 2002 Feb 21;415(6874):926-9
pubmed: 11859373
Nature. 1976 Sep 2;263(5572):56-7
pubmed: 958464
Korean J Parasitol. 1998 Dec;36(4):269-75
pubmed: 9868893
J Immunother Cancer. 2018 Dec 4;6(1):140
pubmed: 30514385
Clin Vaccine Immunol. 2006 Jan;13(1):84-9
pubmed: 16426004
J Hematol Oncol. 2020 Apr 3;13(1):29
pubmed: 32245497
Z Parasitenkd. 1984;70(2):271-4
pubmed: 6426185
Infect Agent Cancer. 2018 Mar 15;13:9
pubmed: 29568324
Oncoimmunology. 2015 Dec 8;5(1):e1115641
pubmed: 26942095
Clin Orthop Relat Res. 1991 Jan;(262):3-11
pubmed: 1984929
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
J Infect Dis. 1971 Dec;124(6):587-92
pubmed: 5127071
Cancer Med. 2019 Jun;8(6):3167-3181
pubmed: 30950210
J Immunother Cancer. 2018 Aug 6;6(1):78
pubmed: 30081947
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Proc Soc Exp Biol Med. 1969 Sep;131(4):1184-8
pubmed: 4309474
Clin Diagn Lab Immunol. 1999 Sep;6(5):765-7
pubmed: 10473533
Curr Pharm Biotechnol. 2012 Jul;13(9):1750-60
pubmed: 21740355
Nat Rev Cancer. 2018 Dec;18(12):727-743
pubmed: 30405213
Mol Ther. 2018 Oct 3;26(10):2476-2486
pubmed: 30064894